SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
Markus Hoffmann,Markus Hoffmann,Prerna Arora,Prerna Arora,Rüdiger Groß,Alina Seidel,Bojan F. Hörnich,Alexander S. Hahn,Nadine Krüger,Luise Graichen,Heike Hofmann-Winkler,Amy Kempf,Amy Kempf,Martin Sebastian Winkler,Sebastian R. Schulz,Hans-Martin Jäck,Bernd Jahrsdörfer,Bernd Jahrsdörfer,Hubert Schrezenmeier,Hubert Schrezenmeier,Martin Müller,Alexander Kleger,Jan Münch,Stefan Pöhlmann,Stefan Pöhlmann +24 more
TLDR
In this article, the authors show that SARS-CoV-2/COVID-19 variants B.1.7 (UK), B.351 (South Africa), and P.1 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies.About:
This article is published in Cell.The article was published on 2021-04-29 and is currently open access. It has received 754 citations till now. The article focuses on the topics: Neutralizing antibody.read more
Citations
More filters
Journal ArticleDOI
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
Pegu, Amarendra, O’Connell, Sarah E.,Stephen D. Schmidt,O’Dell, Sijy, Talana, Chloe A.,Flach, Britta, Jackson, Lisa, Leav, Brett, Ledgerwood, Julie E.,Catherine J. Luke,Makowski, Mat, Nason, Martha C.,Paul C. Roberts,Roederer, Mario, Rebolledo, Paulina A. +7 more
TL;DR: In this article, the authors assess the impact of SARS-CoV-2 variants B.1.7 (Alpha), B.351 (Beta), P.1, 1.429 (Epsilon), B1.526 (Iota), and B.2 (Delta) on binding, neutralizing, and ACE2-competing antibodies elicited by the vaccine mRNA-1273 over seven months.
Journal ArticleDOI
SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.
Daryl Geers,Marc C. Shamier,Susanne Bogers,Gerco den Hartog,Lennert Gommers,Nella N Nieuwkoop,Katharina S. Schmitz,Laurine C Rijsbergen,Jolieke A T van Osch,Emma Dijkhuizen,Gaby Smits,Anouskha D. Comvalius,Djenolan van Mourik,Tom G. Caniels,Marit J. van Gils,Rogier W. Sanders,Bas B. Oude Munnink,Richard Molenkamp,Herbert de Jager,Bart L. Haagmans,Rik L. de Swart,Marion Koopmans,Robert S. van Binnendijk,Rory D. de Vries,Corine H. GeurtsvanKessel +24 more
TL;DR: In this article, the authors studied humoral and cellular immune responses to wild type SARS-CoV-2 and the B.1.7 and B.351 variants of concern in a cohort of 121 BNT162b2 mRNA-vaccinated health care workers.
Journal ArticleDOI
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
Rigel Suzuki,Daichi Yamasoba,Izumi Kimura,Lei Wang,Mai Kishimoto,Jumpei Ito,Yuhei Morioka,Naganori Nao Nao,Hesham Nasser,Keiya Uriu,Yusuke Kosugi,Masumi Tsuda,Yasuko Orba,Michihito Sasaki,Ryo Shimizu,Ryoko Kawabata,Kumiko Yoshimatsu,Hiroyuki Asakura,Mami Nagashima,Kenji Sadamasu,Kazuhisa Yoshimura,Mai Suganami,Akiko Oide,Mika Chiba,H. Ito,Tomokazu Tamura,Kana Tsushima,Haruko Kubo,Zannatul Ferdous,Hiromi Mouri,Miki Iida,Keiko Kasahara,Koshiro Tabata,Mariko Ishizuka,Asako Shigeno,Kenzo Tokunaga,Seiya Ozono,Iwao Yoshida,So Nakagawa,Jiaqi Wu,Miyoko Takahashi,Atsushi Kaneda,Motoaki Seki,Ryoji Fujiki,Bahityar Rahmutulla Nawai,Yutaka Suzuki,Yukie Kashima,Kazumi Abe,Kiyomi Imamura,Kotaro Shirakawa,Akifumi Takaori-Kondo,Yasuhiro Kazuma,Ryosuke Nomura,Yoshihito Horisawa,Kayoko Nagata,Yugo Kawai,Yohei Yanagida,Yusuke Tashiro,Otowa Takahashi,K. Kitazato,Haruyo Hasebe,Chihiro Motozono,Mako Toyoda,Toong Seng Tan,Isaac Ngare,Takamasa Ueno,Akatsuki Saito,Erika P. Butlertanaka,Yurie Tanaka,Nanami Morizako,Hirofumi Sawa,Terumasa Ikeda,Takashi Irie,Keita Matsuno,Shinya Tanaka,Takasuke Fukuhara,Kei Sato +76 more
TL;DR: The emergence of the Omicron variant of SARS-CoV-2 is an urgent global health concern as mentioned in this paper , and statistical modelling suggests that OmicRON has spread more rapidly than the Delta variant in several countries including South Africa.
Journal ArticleDOI
SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity.
Chihiro Motozono,Mako Toyoda,Jiri Zahradnik,Akatsuki Saito,Hesham Nasser,Toong Seng Tan,Isaac Ngare,Izumi Kimura,Keiya Uriu,Yusuke Kosugi,Yuan Yue,Ryo Shimizu,Jumpei Ito,Shiho Torii,Akiko Yonekawa,Nobuyuki Shimono,Yoji Nagasaki,Rumi Minami,Takashi Toya,Noritaka Sekiya,Takasuke Fukuhara,Yoshiharu Matsuura,Gideon Schreiber,Terumasa Ikeda,So Nakagawa,Takamasa Ueno,Kei Sato +26 more
TL;DR: In this article, two recently emerging mutations in the receptor-binding domain of the SARS-CoV-2 spike protein, L452R and Y453F, are shown to increase spike stability, virus infectivity, and fusogenicity.
Journal ArticleDOI
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
Joana Barros-Martins,Swantje I. Hammerschmidt,Anne Cossmann,Ivan Odak,Metodi V. Stankov,Gema Morillas Ramos,Alexandra Dopfer-Jablonka,Annika Heidemann,Christiane Ritter,Michaela Friedrichsen,Christian Schultze-Florey,Inga Ravens,Stefanie Willenzon,Anja Bubke,Jasmin Ristenpart,Anika Janssen,George Ssebyatika,Günter Bernhardt,Jan Münch,Markus Hoffmann,Markus Hoffmann,Stefan Pöhlmann,Stefan Pöhlmann,Thomas Krey,Berislav Bošnjak,Reinhold Förster,Georg M. N. Behrens +26 more
TL;DR: In this article, the authors used the COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd or BioNTech/Pfizer's BNT162b2 (n = 55).
References
More filters
Journal ArticleDOI
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou,Xing-Lou Yang,Xian Guang Wang,Ben Hu,Lei Zhang,Wei Zhang,Hao Rui Si,Yan Zhu,Bei Li,Chao Lin Huang,Hui-Dong Chen,Jing Chen,Yun Luo,Hua Guo,Ren Di Jiang,Meiqin Liu,Ying Chen,Xu Rui Shen,Xi Wang,Xiao Shuang Zheng,Kai Zhao,Quanjiao Chen,Fei Deng,Lin Lin Liu,Bing Yan,Fa Xian Zhan,Yan-Yi Wang,Gengfu Xiao,Zhengli Shi +28 more
TL;DR: Identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China, and it is shown that this virus belongs to the species of SARSr-CoV, indicates that the virus is related to a bat coronav virus.
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
Bette T. Korber,Will Fischer,Sandrasegaram Gnanakaran,Hyejin Yoon,James Theiler,Werner Abfalterer,Nick Hengartner,Elena E. Giorgi,Tanmoy Bhattacharya,Brian T. Foley,Kathryn M. Hastie,Matthew Parker,David G Partridge,Cariad Evans,Timothy M. Freeman,Thushan I de Silva,Adrienne Angyal,Rebecca Brown,Laura Carrilero,Luke R. Green,Luke R. Green,Luke R. Green,Danielle C. Groves,Katie Johnson,Alexander J Keeley,Benjamin B Lindsey,Paul J. Parsons,Mohammad Raza,Sarah Rowland-Jones,Nikki Smith,Rachel Tucker,Dennis Wang,Matthew Wyles,Charlene McDanal,Lautaro G. Perez,Haili Tang,Alex Moon-Walker,Alex Moon-Walker,Alex Moon-Walker,Sean P. J. Whelan,Celia C. LaBranche,Erica Ollmann Saphire,David C. Montefiori +42 more
TL;DR: A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become the most prevalent form in the global pandemic, and it is found that the G614 variant grows to higher titer as pseudotyped virions.
Journal ArticleDOI
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Alba Grifoni,Daniela Weiskopf,Sydney I. Ramirez,Sydney I. Ramirez,Jose Mateus,Jennifer M. Dan,Jennifer M. Dan,Carolyn Rydyznski Moderbacher,Stephen A. Rawlings,Aaron Sutherland,Lakshmanane Premkumar,Ramesh Jadi,Daniel Marrama,Aravinda M. de Silva,April Frazier,Aaron F. Carlin,Jason A. Greenbaum,Bjoern Peters,Bjoern Peters,Florian Krammer,Davey M. Smith,Shane Crotty,Shane Crotty,Alessandro Sette,Alessandro Sette +24 more
TL;DR: Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2−specific CD8+ and CD4+ T cells were identified in ∼70% and 100% of COVID-19 convalescent patients, respectively, suggesting cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS.
Related Papers (5)
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Pengfei Wang,Manoj S. Nair,Lihong Liu,Sho Iketani,Sho Iketani,Yang Luo,Yicheng Guo,Maple Wang,Jian Yu,Baoshan Zhang,Peter D. Kwong,Peter D. Kwong,Barney S. Graham,John R. Mascola,Jennifer Y Chang,Jennifer Y Chang,Michael T. Yin,Michael T. Yin,Magdalena E. Sobieszczyk,Magdalena E. Sobieszczyk,Christos A. Kyratsous,Lawrence Shapiro,Lawrence Shapiro,Zizhang Sheng,Yaoxing Huang,David D. Ho,David D. Ho +26 more
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
Bette T. Korber,Will Fischer,Sandrasegaram Gnanakaran,Hyejin Yoon,James Theiler,Werner Abfalterer,Nick Hengartner,Elena E. Giorgi,Tanmoy Bhattacharya,Brian T. Foley,Kathryn M. Hastie,Matthew Parker,David G Partridge,Cariad Evans,Timothy M. Freeman,Thushan I de Silva,Adrienne Angyal,Rebecca Brown,Laura Carrilero,Luke R. Green,Luke R. Green,Luke R. Green,Danielle C. Groves,Katie Johnson,Alexander J Keeley,Benjamin B Lindsey,Paul J. Parsons,Mohammad Raza,Sarah Rowland-Jones,Nikki Smith,Rachel Tucker,Dennis Wang,Matthew Wyles,Charlene McDanal,Lautaro G. Perez,Haili Tang,Alex Moon-Walker,Alex Moon-Walker,Alex Moon-Walker,Sean P. J. Whelan,Celia C. LaBranche,Erica Ollmann Saphire,David C. Montefiori +42 more
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
Nicholas G Davies,Sam Abbott,Rosanna C. Barnard,Christopher I Jarvis,Adam J. Kucharski,James D Munday,Carl A. B. Pearson,Timothy W Russell,Damien C. Tully,Alex D. Washburne,Tom Wenseleers,Amy Gimma,William Waites,Kerry L. M. Wong,Kevin van Zandvoort,Justin D. Silverman,Karla Diaz-Ordaz,Ruth H. Keogh,Rosalind M Eggo,Sebastian Funk,Mark Jit,Katherine E. Atkins,Katherine E. Atkins,W. John Edmunds +23 more